Radionuclide 131I-labeled albumin-indocyanine green nanoparticles for synergistic combined radio-photothermal therapy of anaplastic thyroid cancer

• Published in: Frontiers in oncology Vol. 12; p. 889284
• Main Authors: Zhang, Xuemei, Yan, Ziyu, Meng, Zhaowei, Li, Ning, Jia, Qiang, Shen, Yiming, Ji, Yanhui
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 25.07.2022
• Subjects: anaplastic thyroid cancer; human serum albumin; indocyanine green; Oncology; photothermal therapy; radionuclide therapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.889284

Objectives Anaplastic thyroid cancer (ATC) cells cannot retain the radionuclide iodine 131 ( 131 I) for treatment due to the inability to uptake iodine. This study investigated the feasibility of combining radionuclides with photothermal agents in the diagnosis and treatment of ATC. Methods 131 I was labeled on human serum albumin (HSA) by the standard chloramine T method. 131 I-HSA and indocyanine green (ICG) were non-covalently bound by a simple stirring to obtain 131 I-HSA-ICG nanoparticles. Characterizations were performed in vitro . The cytotoxicity and imaging ability were investigated by cell/ in vivo experiments. The radio-photothermal therapy efficacy of the nanoparticles was evaluated at the cellular and in vivo levels. Results The synthesized nanoparticles had a suitable size (25–45 nm) and objective biosafety. Under the irradiation of near-IR light, the photothermal conversion efficiency of the nanoparticles could reach 24.25%. In vivo fluorescence imaging and single-photon emission CT (SPECT)/CT imaging in small animals confirmed that I-HSA-ICG/ 131 I-HSA-ICG nanoparticles could stay in tumor tissues for 4–6 days. Compared with other control groups, 131 I-HSA-ICG nanoparticles had the most significant ablation effect on tumor cells under the irradiation of an 808-nm laser. Conclusions In summary, 131 I-HSA-ICG nanoparticles could successfully perform dual-modality imaging and treatment of ATC, which provides a new direction for the future treatment of iodine-refractory thyroid cancer.